多利培南（S-4661）对从囊性纤维化患者中分离出的多重耐药革兰氏阴性杆菌的体外活性。
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
作者信息
Chen Yunhua, Garber Elizabeth, Zhao Qiuqu, Ge Yigong, Wikler Matthew A, Kaniga Koné, Saiman Lisa
机构信息
Department of Pediatrics, Columbia University, 622 West 168th St., PH4W-470, New York, NY 10032, USA.
出版信息
Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1. doi: 10.1128/AAC.49.6.2510-2511.2005.
Abstract
Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n=200 strains), nonmucoid P. aeruginosa (n=200), and Burkholderia cepacia complex (n=200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 microg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.
摘要
多利培南对从囊性纤维化患者中分离出的黏液型铜绿假单胞菌（n = 200株）、非黏液型铜绿假单胞菌（n = 200）和洋葱伯克霍尔德菌复合体（n = 200）的多药耐药菌株的50%抑制浓度（MIC50）和90%抑制浓度（MIC90）分别为8和32、8和64以及8和32微克/毫升。多利培南的活性比已有的抗菌药物略好。
相似文献
1
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.多利培南（S-4661）对从囊性纤维化患者中分离出的多重耐药革兰氏阴性杆菌的体外活性。
Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1. doi: 10.1128/AAC.49.6.2510-2511.2005.
2
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.多利培南对来自囊性纤维化和非囊性纤维化患者的铜绿假单胞菌和洋葱伯克霍尔德菌分离株的体外活性。
Antimicrob Agents Chemother. 2006 Feb;50(2):819-21. doi: 10.1128/AAC.50.2.819-821.2006.
3
4
In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex.S-(3,4-二氯苄基)异硫脲盐酸盐和新型结构相关化合物对包括铜绿假单胞菌和洋葱伯克霍尔德菌复合体在内的多重耐药菌的体外活性。
Int J Antimicrob Agents. 2012 Jan;39(1):27-32. doi: 10.1016/j.ijantimicag.2011.08.015. Epub 2011 Oct 10.
5
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.多黏菌素联合多利培南在体外药代动力学/药效学模型中对多重耐药铜绿假单胞菌在多个接种量下的协同杀伤作用。
Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95. doi: 10.1128/AAC.05298-11. Epub 2011 Sep 12.
6
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.从囊性纤维化患者中分离出的洋葱伯克霍尔德菌复合体的药敏性及协同性研究。
Antimicrob Agents Chemother. 2007 Mar;51(3):1085-8. doi: 10.1128/AAC.00954-06. Epub 2006 Dec 11.
7
In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients.多利培南对非囊性纤维化患者伯克霍尔德菌复合体分离株的体外活性。
Antimicrob Agents Chemother. 2011 Mar;55(3):1320-1. doi: 10.1128/AAC.01386-10. Epub 2010 Dec 28.
8
Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern.从囊性纤维化患者痰液培养物中分离出的微生物的抗菌药敏性：耐甲氧西林金黄色葡萄球菌成为严重问题。
Microb Pathog. 2016 Nov;100:201-204. doi: 10.1016/j.micpath.2016.09.015. Epub 2016 Sep 22.
9
Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.头孢他啶-阿维巴坦对从囊性纤维化患者呼吸道样本中分离出的多重耐药菌的抗菌活性趋势。
Transpl Infect Dis. 2018 Oct;20(5):e12955. doi: 10.1111/tid.12955. Epub 2018 Jun 25.
10
Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.头孢他洛酯-他唑巴坦和其他抗菌药物对洋葱伯克霍尔德菌复合体和脆弱拟杆菌的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00766-17. Print 2017 Sep.
引用本文的文献
1
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.囊性纤维化中碳青霉烯类耐药的现状：系统评价和荟萃分析。
Yale J Biol Med. 2022 Dec 22;95(4):495-506. eCollection 2022 Dec.
2
Spontaneous Bacterial Peritonitis by Complex: A Rare, Difficult to Treat Infection in Decompensated Cirrhotic Patients.复杂自发性细菌性腹膜炎：失代偿期肝硬化患者中一种罕见且难治的感染
J Clin Exp Hepatol. 2017 Jun;7(2):102-106. doi: 10.1016/j.jceh.2016.08.008. Epub 2016 Aug 28.
3
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.MIC评分是一种用于比较细菌对抗生素敏感性的新工具，应用于比较铜绿假单胞菌临床菌株对不同碳青霉烯类抗生素的敏感性。
J Antibiot (Tokyo). 2016 Nov;69(11):806-810. doi: 10.1038/ja.2016.38. Epub 2016 Mar 30.
4
New antimicrobial strategies in cystic fibrosis.囊性纤维化的新抗菌策略。
Paediatr Drugs. 2010 Dec 1;12(6):343-52. doi: 10.2165/11316240-000000000-00000.
5
Characteristics of doripenem: a new broad-spectrum antibiotic.多利培南的特性：一种新型广谱抗生素。
Drug Des Devel Ther. 2009 Sep 21;3:173-90. doi: 10.2147/dddt.s3083.
6
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.头孢吡肟：在抗菌药物耐药性不断增加的时代的重新评估。
Expert Rev Anti Infect Ther. 2008 Dec;6(6):805-24. doi: 10.1586/14787210.6.6.805.
7
Doripenem: a review of its use in the treatment of bacterial infections.多利培南：其在治疗细菌感染中的应用综述
Drugs. 2008;68(14):2021-57. doi: 10.2165/00003495-200868140-00007.
8
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.通过模拟人体暴露情况对多黏菌素B进行针对铜绿假单胞菌的体内药效学分析。 （你提供的原文中药物名称有误，doripenem是多尼培南，而你给出的译文是多黏菌素B，我按照正确的doripenem翻译为：通过模拟人体暴露情况对多尼培南进行针对铜绿假单胞菌的体内药效学分析。）
Antimicrob Agents Chemother. 2008 Jul;52(7):2497-502. doi: 10.1128/AAC.01252-07. Epub 2008 May 5.
9
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.通过最低抑菌浓度（MIC）和时间-杀菌分析测定多利培南的抗厌氧活性比较
Antimicrob Agents Chemother. 2008 Jan;52(1):365-73. doi: 10.1128/AAC.00910-07. Epub 2007 Oct 15.
本文引用的文献
1
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.美罗培南与妥布霉素联合用药对比头孢他啶与妥布霉素联合用药治疗囊性纤维化患者急性肺部加重的疗效和安全性。
Chest. 2005 Oct;128(4):2336-46. doi: 10.1378/chest.128.4.2336.
2
In vitro antimicrobial activity of doripenem, a new carbapenem.新型碳青霉烯类药物多利培南的体外抗菌活性
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96. doi: 10.1128/AAC.48.4.1384-1396.2004.
3
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.多利培南对具有特征性β-内酰胺酶的肠杆菌科细菌和不动杆菌属细菌的分离株、突变株及接合子的比较活性
Antimicrob Agents Chemother. 2004 Apr;48(4):1313-9. doi: 10.1128/AAC.48.4.1313-1319.2004.
4
Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.囊性纤维化患者的感染控制建议：微生物学、重要病原体以及预防患者间传播的感染控制措施。
Infect Control Hosp Epidemiol. 2003 May;24(5 Suppl):S6-52. doi: 10.1086/503485.
5
Burkholderia cepacia epidemiology and pathogenesis: implications for infection control.洋葱伯克霍尔德菌的流行病学与发病机制：对感染控制的启示
Curr Opin Pulm Med. 1998 Nov;4(6):337-41. doi: 10.1097/00063198-199811000-00005.
6
Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.
Chemotherapy. 2000 May-Jun;46(3):184-7. doi: 10.1159/000007276.
7
In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.新型碳青霉烯类药物S-4661的体外和体内抗菌活性
Antimicrob Agents Chemother. 1998 Jan;42(1):94-9. doi: 10.1128/AAC.42.1.94.
8
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.从囊性纤维化患者（包括移植候选者）中分离出的多重耐药铜绿假单胞菌的抗生素敏感性
Clin Infect Dis. 1996 Sep;23(3):532-7. doi: 10.1093/clinids/23.3.532.
9
Microbiology of airway disease in patients with cystic fibrosis.囊性纤维化患者气道疾病的微生物学
Clin Microbiol Rev. 1991 Jan;4(1):35-51. doi: 10.1128/CMR.4.1.35.
Zotero 插件